专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2007084630A2 MUTANT JAK3 KINASE IN HUMAN LEUKEMIA 审中-公开
标题翻译： MUTANT JAK3激活人类LEUKEMIA
公开(公告)号：WO2007084630A2
公开(公告)日：2007-07-26
申请号：PCT/US2007001359
申请日：2007-01-19
申请人： CELL SIGNALING TECHNOLOGY INC , GOSS VALERIE , GU TING-LEI , POLAKIEWICZ ROBERTO , DRUKER BRIAN , WALTERS DENISE
发明人： GOSS VALERIE , GU TING-LEI , POLAKIEWICZ ROBERTO , DRUKER BRIAN , WALTERS DENISE
IPC分类号： C12N9/12
CPC分类号： C12N9/1205 , C12Q1/6886 , C12Q2600/106 , C12Q2600/136
摘要： In accordance with the invention, a novel activating mutation (alanine 572 to valine) in JAK3 kinase has been discovered in human acute myelogenous leukemia (AML). The mutant JAK3 kinase was confirmed to drive the proliferation and survival of acute megakaryoblastic leukemia (AML-M7). The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant JAK3 kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the mutant polypeptides. The disclosed identification of this new mutant protein and enables new methods for determining the presence of mutant JAK3 kinase polypeptides in a biological sample, methods for screening for compounds that inhibit the mutant proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides, which are also provided by the invention.
摘要翻译：根据本发明，已经在人急性骨髓性白血病（AML）中发现JAK3激酶中的新的活化突变（丙氨酸572至缬氨酸）。证实突变体JAK3激酶能够驱动急性巨核细胞白血病（AML-M7）的增殖和存活。因此，本发明部分地提供分离的多核苷酸和编码所公开的突变体JAK3激酶多肽的载体，用于检测其的探针，分离的突变多肽，重组多肽和用于检测突变多肽的试剂。所公开的这种新突变蛋白质的鉴定，并且使得能够确定生物样品中突变体JAK3激酶多肽的存在的新方法，用于筛选抑制突变蛋白质的化合物的方法，以及抑制以突变体为特征的癌症进展的方法多核苷酸或多肽，其也由本发明提供。

2. 发明申请

WO2007075933A2 TRANSLOCATION AND MUTANT CSF1R KINASE IN HUMAN LEUKEMIA 审中-公开
标题翻译：人淋巴细胞转移和突变CSF1R激酶
公开(公告)号：WO2007075933A2
公开(公告)日：2007-07-05
申请号：PCT/US2006048867
申请日：2006-12-21
申请人： CELL SIGNALING TECHNOLOGY INC , GU TING-LEI , GOSS VALERIE , POLAKIEWICZ ROBERTO , DRUKER BRIAN , WALTERS DENISE
发明人： GU TING-LEI , GOSS VALERIE , POLAKIEWICZ ROBERTO , DRUKER BRIAN , WALTERS DENISE
IPC分类号： C07K14/705
CPC分类号： C12N9/12 , C07K2319/85
摘要： In accordance with the invention, a novel gene translocation, (3p21 , 5q33), in human myelogenous leukemia (AML) that results in a fusion protein combining part of RNA Binding Protein-6 (RBM6) with Macrophage Colony Stimulating Factor-1 Receptor (CSF1 R) kinase has now been identified. The RBM6-CSF1 R fusion protein and truncated CSF1R kinase itself, which both retain CSF1 R tyrosine kinase activity, were confirmed to drive the proliferation and survival of acute megakaryoblastic leukemia (AML-M7). The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant CSF1R kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The disclosed identification of this new fusion protein and truncated kinase enables new methods for determining the presence of these mutant CSF 1 R kinase polypeptides in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides, which are also provided by the invention.
摘要翻译：根据本发明，在人骨髓性白血病（AML）中的新型基因易位（3p21,5q33），其导致将部分RNA结合蛋白-6（RBM6）与巨噬细胞集落刺激因子-1受体（RBF6）结合的融合蛋白 CSF1R）激酶已被鉴定。证实了RBM6-CSF1R融合蛋白和截短的CSF1R激酶本身都保留CSF1R酪氨酸激酶活性，以驱动急性巨核细胞白血病（AML-M7）的增殖和存活。因此，本发明部分地提供分离的多核苷酸和编码所公开的突变型CSF1R激酶多肽的载体，用于检测其的探针，分离的突变多肽，重组多肽和用于检测融合和截短的多肽的试剂。所公开的这种新的融合蛋白和截短的激酶的鉴定使得能够确定生物样品中这些突变型CSF1R激酶多肽的存在的新方法，用于筛选抑制蛋白质的化合物的方法，以及抑制癌症进展的方法其特征在于突变体多核苷酸或多肽，其也由本发明提供。

3. 发明申请

WO2007015886A8 PHOSPHORYLATED PROTEIN MARKERS OF GLEEVEC-RESISTANT CHRONIC MYELOGENOUS LEUKEMIA 审中-公开
标题翻译：耐药性慢性髓性白血病的磷酸化蛋白标记
公开(公告)号：WO2007015886A8
公开(公告)日：2008-10-30
申请号：PCT/US2006027936
申请日：2006-07-19
申请人： CELL SIGNALING TECHNOLOGY INC , GOSS VALERIE , LEE KIMBERLY , POLAKIEWICZ ROBERTO , DRUKER BRIAN , DENINGER MICHAEL , GRISWOLD IAN
发明人： GOSS VALERIE , LEE KIMBERLY , POLAKIEWICZ ROBERTO , DRUKER BRIAN , DENINGER MICHAEL , GRISWOLD IAN
IPC分类号： G01N33/53 , C07K14/00 , C07K16/00
CPC分类号： G01N33/57426 , C12Q1/485 , G01N2500/04 , G01N2800/52

4. 发明专利

CA2675534A1 MUTANT JAK3 KINASE IN HUMAN LEUKEMIA 未知
公开(公告)号：CA2675534A1
公开(公告)日：2007-07-26
申请号：CA2675534
申请日：2007-01-19
申请人： CELL SIGNALING TECHNOLOGY INC
发明人： GOSS VALERIE , GU TING-LEI , POLAKIEWICZ ROBERTO , DRUKER BRIAN , WALTERS DENISE
IPC分类号： C12N15/54 , C07K16/40 , C12N9/12 , C12Q1/48 , C12Q1/68 , G01N33/573 , G01N33/574
摘要： In accordance with the invention, a novel activating mutation (alanine 57 2 to valine) in JAK3 kinase has been discovered in human acute myelogenous l eukemia (AML). The mutant JAK3 kinase was confirmed to drive the proliferati on and survival of acute megakaryoblastic leukemia (AML-M7). The invention t herefore provides, in part, isolated polynucleotides and vectors encoding th e disclosed mutant JAK3 kinase polypeptides, probes for detecting it, isolat ed mutant polypeptides, recombinant polypeptides, and reagents for detecting the mutant polypeptides. The disclosed identification of this new mutant pr otein and enables new methods for determining the presence of mutant JAK3 ki nase polypeptides in a biological sample, methods for screening for compound s that inhibit the mutant proteins, and methods for inhibiting the progressi on of a cancer characterized by the mutant polynucleotides or polypeptides, which are also provided by the invention.

5. 发明公开

EP1984523A4 MUTANT JAK3 KINASE IN HUMAN LEUKEMIA 审中-公开
标题翻译：突变体JAK3激酶在白血病人
公开(公告)号：EP1984523A4
公开(公告)日：2010-03-03
申请号：EP07718179
申请日：2007-01-19
申请人： CELL SIGNALING TECHNOLOGY INC
发明人： GOSS VALERIE , GU TING-LEI , POLAKIEWICZ ROBERTO , DRUKER BRIAN , WALTERS DENISE
IPC分类号： C12Q1/68 , C07K14/82 , C12N15/64 , C12P21/06
CPC分类号： C12N9/1205 , C12Q1/6886 , C12Q2600/106 , C12Q2600/136

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式